Stocks › ORKA
Oruka Therapeutics, Inc. (ORKA) stock analysis
WEAK BUY 23% confidence · analysed Nov 4, 2026
On Nov 4, 2026, our model rated Oruka Therapeutics, Inc. (ORKA) WEAK BUY with 23% confidence at a price of $99.55. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 81, above 70, which is overbought: buyers have been very aggressive and a pause or pullback is common from here.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is about normal (0.9x the 20-day average).
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $115.52 and the swing low is $25.23; traders often treat these as resistance and support.
Fundamentals
The company reports a profit margin of 0.0%.
In its latest quarter it earned $-0.55 per share, which missed the $-0.50 analysts expected.
Wall Street's average rating is 1.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $156.17.
The next earnings report is expected around Nov 11, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $99.55, a target of $108.35 (+8.8%) and a stop-loss at $89.51 (-10.1%).
That is a reward-to-risk ratio of about 0.9 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 10, 2026 whatever the price does.
The model's one-paragraph read
Leans BUY — composite score +0.23 (WEAK BUY). Technicals: RSI 80.7, MACD bullish, price above SMA50. Fundamentals: margin 0.0%. Financial results: last EPS surprise -10.0%, next earnings 2026-11-11. Smart Money Concepts: ranging / no clear structure. FinGPT news read: positive. Suggested levels: entry $99.55, target $108.35, stop-loss $89.51, exit by 2026-11-10 (exit before next earnings (2026-11-11) -- this signal doesn't price in that report).
Past ratings for ORKA
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 4, 2026 | WEAK BUY | 23% | $99.55 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on ORKA
- Nov 3, 2026: Oruka Therapeutics to Participate in Multiple Upcoming Conferences (GlobeNewswire)
Other Healthcare stocks we cover
OSCR · PCRX · PCVX · PEN · PFE · PGNY · PHG · PHR · PRGO · PTGX · QURE · RCUS
Frequently asked questions
Is ORKA a buy right now?
As of Nov 4, 2026, our automated model rates Oruka Therapeutics, Inc. (ORKA) WEAK BUY with 23% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for ORKA?
The model's most recent plan targets $108.35 with a stop-loss at $89.51, from an entry near $99.55.
When does Oruka Therapeutics, Inc. report earnings next?
The next earnings report is expected around Nov 11, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.